Genetron Holdings Ltd. ADR (GTH): Price and Financial Metrics
GET POWR RATINGS... FREE!
GTH Stock Price Chart Interactive Chart >
GTH Price/Volume Stats
| Current price | $1.57 | 52-week high | $21.97 |
| Prev. close | $1.61 | 52-week low | $1.25 |
| Day low | $1.56 | Volume | 63,100 |
| Day high | $1.65 | Avg. volume | 285,256 |
| 50-day MA | $1.60 | Dividend yield | N/A |
| 200-day MA | $6.22 | Market Cap | 142.25M |
Genetron Holdings Ltd. ADR (GTH) Company Bio
Genetron Holdings, Ltd. engages in precision oncology. It provides cancer molecular profiling by using technologies in molecular biology and data science to transform cancer treatment. It products and services include diagnosis and monitoring through both LDT and IVD products. Its LDT portfolio consists of both specifically designed focused and comprehensive gene panel testing services. It also develops liver cancer early screening products. The company was founded by Si Zhen Wang, Hai Yan, and Wei Wu He in 2015 and is headquartered in Beijing, China.
Latest GTH News From Around the Web
Below are the latest news stories about Genetron Holdings Ltd that investors may wish to consider to help them evaluate GTH as an investment opportunity.
Genetron Holdings (GTH) Investor Presentation - SlideshowThe following slide deck was published by Genetron Holdings Limited in conjunction with this event.... |
Genetron Health Announces Companion Diagnostic Collaboration Agreement with HUTCHMED''s ORPATHYS® for NSCLCBEIJING, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ: GTH ), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has signed a collaboration agreement with HUTCHMED (China) Limited (" HUTCHMED ") (Nasdaq/AIM: HCM; HKEX: 13) for the joint development of a companion diagnostic (CDx) test for ORPATHYS ® (savolitinib) in China. Under the agreement, the partners plan to jointly validate and register Genetron Health''s approved NGS-based 8-gene Lung Cancer Assay (Tissue) as CDx for ORPATHYS ® . Developed based on Genetron Health''s proprietary One-step Seq method, the 8-gene Lung Ca... |
Genetron Health Announces Companion Diagnostic Collaboration Agreement with HUTCHMEDs ORPATHYS® for NSCLCBEIJING, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (Genetron Health or the Company, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has signed a collaboration agreement with HUTCHMED (China) Limited ( HUTCHMED ) (Nasdaq/AIM: HCM; HKEX: 13) for the joint development of a companion diagnostic (CDx) test for ORPATHYS ® (savolitinib) in China. |
Genetron Health Announces Companion Diagnostic Collaboration Agreement with HUTCHMED’s ORPATHYS® for NSCLCBEIJING, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has signed a collaboration agreement with HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) for the joint development of a companion diagnostic (CDx) test for |
Inspira, Genetron lead healthcare gainers; Amphastar, NRx Pharmaceuticals among losersGainers: Inspira Technologies Oxy (IINN) +23%. Genetron (GTH) +15% |
GTH Price Returns
| 1-mo | N/A |
| 3-mo | -28.31% |
| 6-mo | -74.26% |
| 1-year | -92.78% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -74.26% |
| 2021 | -56.43% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...